Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

KB Design & Promotion Ltd

KB Design and Promotion Limited was established in 1988, with over 20 years experience delivering global solutions for our clients.  Whilst specializing in delivering promotional products worldwide, we creatively source and supply a range of products, which promote your products.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

Dice Medical Communications Logo

Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop great pharmaceutical brands. We do this by creating Pharmacohesion™.

View Profile

Advertising, Branding, Conference/meetings/events, Creative and design, Digital communications, Market access, Market research, Marketing consultancies, Medical communications, Medical education, Patient support and adherence, Sales, Training

- PMLiVE

Innovative Trials

Innovative Trials is a leading global clinical trial patient recruitment company. With over 10 years’ of experience, Innovative Trials deploys ‘boots-on-the-ground’ recruitment experts in over 70 countries, addressing individual sites’…

View Profile

Sales

Company Details

KB Design & Promotion Ltd
10 Foundry Court, Foundry Lane, Horsham, West Sussex, RH13 5PY, United Kingdom
+44 (0)1403 262 499
Contact KB Design & Promotion Ltd
Website

 Latest Content from PMHub 

Showcasing our multichannel capabilities in Berlin

White Papers and Resources | September 22, 2016 | Anthill Agency

Join Anthill for conferences in October to understand how to bring value to HCPs through multichannel communications

DAM and CMS: managing assets to maximise adoption and value

White Papers and Resources | September 19, 2016 | Blue Latitude Health

Senior Account Executive Dave Wood talks us through what DAM and CMS are, the role they play in the future of healthcare marketing, and how they can be best utilised...

Tenth Lucid Academy module delivered – nurturing talent and driving excellence

Press Releases | September 15, 2016 | Lucid Group Communications Limited

Celebrating the success of the Lucid Academy

Lucid launch new recruitment campaign to attract top talent in medical writing

Press Releases | September 8, 2016 | Lucid Group Communications Limited

We will offer talented writers an exclusive, tailor-made package to suit their individual needs and desires. We want you to define the framework of your Lucid Life contract – from...

Knowing your audience is key to successful medical education

Press Releases | September 7, 2016 | Lucid Group Communications Limited

Lucid Group understands that the goals of medical education are to disseminate best practice and advance patient outcomes. Our approach to meeting these goals centres on our appreciation of both...

How to enable each healthcare professional to fully understand your product

White Papers and Resources | September 7, 2016 | Anthill Agency

Read these three articles to understand how working at an individual level benefits all customers:

Alzheimer’s disease: reviewing the immediate treatment horizon

White Papers and Resources | September 1, 2016 | Blue Latitude Health

Account Manager Stuart Goodman takes a look at some of the promising categories of Phase 3 treatments that could soon be available to patients with Alzheimer's disease.

A stumble, but not a fall – what’s next for Opdivo?

White Papers and Resources | August 25, 2016 | Blue Latitude Health

Blue Latitude Health's Louis Perdios talks about the daunting challenges faced by BMS after Opdivo's disappointing results.

Meet Anthill at conferences in London

White Papers and Resources | August 19, 2016 | Anthill Agency

October, the month of multichannel pharma marketing in London. Meet us at DigiPharm and Multichannel Excellence Summit

Immuno-oncology; bringing patients closer to treatment

White Papers and Resources | August 18, 2016 | Blue Latitude Health

What do the new immunotherapies in oncology mean for those stakeholders who need to understand and make decisions about treatment?